Excel-based tool for pharmacokinetically guided dose adjustment of paclitaxel

Therapeutic Drug Monitoring

Volumn 37, Issue 6, 2015, Pages 725-732

  Kraff, Stefanie ^a   Lindauer, Andreas ^a,b   Joerger, Markus ^c   Salamone, Salvatore J ^d   Jaehde, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Exprimo NV   (Belgium)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d SALADAX BIOMEDICAL INC   (United States)

Author keywords

Individualized dosing; Microsoft Excel; NONMEM; Paclitaxel; Therapeutic drug monitoring

Indexed keywords

BILIRUBIN; CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BAYES THEOREM; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; COMPUTER INTERFACE; COMPUTER PROGRAM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVARY CANCER; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SOLID TUMOR; BIOLOGICAL MODEL; CHEMICALLY INDUCED; DOSE RESPONSE; MIDDLE AGED; NONLINEAR SYSTEM; PROCEDURES; VALIDATION STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BAYES THEOREM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEUTROPENIA; NONLINEAR DYNAMICS; PACLITAXEL;

EID: 84947939478     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000206     Document Type: Article

References (34)

1. Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer. 2002; 38:1677-1684.
2. Kaestner SA, Sewell GJ. Chemotherapy dosing part I: scientific basis for current practice and use of body surface area. Clin Oncol (R Coll Radiol). 2007;19:23-37.
3. Mathijssen RHJ, de Jong FA, Loos WJ, et al. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist. 2007;12:913-923.
4. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748-1756.
5. Taxol prescribing information. Bristol-Myers Squibb. 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/020262s049lbl. pdf. Accessed October 18, 2014.
6. Joerger M, Huitema ADR, Richel DJ, et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res. 2007;13:6410-6418.
7. Miller AA, Rosner GL, Egorin MJ, et al. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and phar-macodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res. 2004;10:8325-8331.
8. Ohtsu T, Sasaki Y, Tamura T, et al. Clinical pharmacokinetics and phar-macodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res. 1995;1:599-606.
9. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995;13:180-190.
10. Joerger M, Kraff S, Huitema ADR, et al. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clin Pharmacokinet. 2012;51:607-617.
11. ClinicalTrials.Gov [database online]. Central European Society for Anticancer Research-EWIV (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring (CEPAC-TDM study) [Clinicaltrial.gov identifier: NCT01326767]. 2011. Available at: http://clinicaltrials.gov. Accessed October 18, 2014.
12. Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol. 2002;16:253-262.
13. Huitema AD, Mathôt RA, Tibben MM, et al. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. Clin Pharmacol Ther. 2000;67:621-630.
14. Wallin JE, Friberg LE, Karlsson MO. A tool for neutrophil guided dose adaptation in chemotherapy. Comput Methods Programs Biomed. 2009; 93:283-291.
15. Wallin JE, Friberg LE, Fasth A, et al. Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: new initial dosage suggestions and a model-based dosage adjustment tool. Ther Drug Monit. 2009;31:457-466.
16. Sandström M, Karlsson MO, Ljungman P, et al. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. Bone Marrow Transpl. 2001;28:657-664.
17. Joerger M, Huitema ADR, van den Bongard DHJG, et al. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clin Cancer Res. 2006;12:2150-2157.
18. ALGLIB, Bochkanov S, Bystritsky V. Available at: http://www.alglib. net/. Accessed October 18, 2014.
19. Jelliffe RW, Schumitzky A, van Guilder M, et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit. 1993;15:380-393.
20. Sheiner LB, Beal S, Rosenberg B, et al. Forecasting individual pharmacokinetics. Clin Pharmacol Ther. 1979;26:294-305.
21. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. JPharmacokinet Biopharm. 1981;9:503-512.
22. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Int Med. 1916;17:863-871.
23. Dansirikul C, Choi M, Duffull SB. Estimation of pharmacokinetic parameters from non-compartmental variables using Microsoft Excel. Comput Biol Med. 2005;35:389-403.
24. McCoy AT, Bartels MJ, Rick DL, et al. TK Modeler version 1.0, a Microsoft Excel-based modeling software for the prediction of diurnal blood/plasma concentration for toxicokinetic use. Regul Toxicol Pharmacol. 2012;63:333-343.
25. Meineke I, Brockmöller J. Simulation of complex pharmacokinetic models in Mcrosoft Excel. Comput Methods Programs Biomed. 2007;88:239-245.
26. Walther JL, Bartlett DW, Chew W, et al. Downloadable computer models for renal replacement therapy. Kidney Int. 2006;69:1056-1063.
27. Zhang Y, Huo M, Zhou J, et al. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99:306-314.
28. Haddad S, Pelekis M, Krishnan K. A methodology for solving physiologically based pharmacokinetic models without the use of simulation software. Toxicol Lett. 1996;85:113-126.
29. Jongeneelen FJ, Berge WF. A generic, cross-chemical predictive PBTK model with multiple entry routes running as application in MS Excel; design of the model and comparison of predictions with experimental results. Ann Occup Hyg. 2011;55:841-864.
30. Salinger DH, McCune JS, Ren AG, et al. Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approach. Clin Cancer Res. 2006;12:4888-4898.
31. Wu G. Calculating predictive performance: a user's note. Pharmacol Res. 1995;31:393-399.
32. Bustad A, Terziivanov D, Leary R, et al. Parametric and nonparametric population methods: their comparative performance in analyzing a clinical data set and two Monte Carlo simulation studies. Clin Pharmacokinet. 2006;45:365-383.
33. Leary R, Jelliffe R, Schumitzky A, et al. A unified parametric/nonparametric approach to population PK/PD modeling. Paper presented at: 11th Annual Meeting of the Population Approach Group in Europe; 6-7 June, 2002; Paris, France.
34. Jelliffe R, Bayard D, Milman M, et al. Achieving target goals most precisely using nonparametric compartmental models and "multiple model" design of dosage regimens. Therap Drug Monit. 2000;22:346-353.